Aventis Gammar-P Recall
This article was originally published in The Pink Sheet Daily
Executive Summary
Aventis Behring is recalling two lots of Gammar-P intravenous 10 gram due to "an increased frequency of non-serious, labeled adverse events associated with allergic reactions," FDA said April 2
You may also be interested in...
Baxter Recalls Gammagard S/D
One lot is associated with allergic reactions, FDA says. Two of the adverse events have involved airway events and all reactions have required medical intervention, although none have been life threatening.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.